Evidence map›Paper›PMID 41193460›Full record

ArticleBlood cancer journal2025

Telomere occupancy by TRF2 is altered by KIT mutations and correlates with mastocytosis regression.

Julie Bruneau, Sophie Georgin-Lavialle, Sophia Ladraa, Zakia Belaid, Isabelle Plo, Sébastien Letard, Erinn Soucie, Irena Draskovic, Nicolas Goudin, Marie Bouillié and 14 more

Abstract read
In one paragraph

Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Julie Bruneau *INSERM U1163, Laboratoire de physiopathologie et de traitement des troubles hématologiques, Institut Imagine, Université Paris Cité, Hôpital Universitaire Necker - Enfants Malades, Paris, France. julie.bruneau@aphp.fr.ORCID 0000-0001-5519-8489
Sophie Georgin-Lavialle *INSERM U1163, Laboratoire de physiopathologie et de traitement des troubles hématologiques, Institut Imagine, Université Paris Cité, Hôpital Universitaire Necker - Enfants Malades, Paris, France.
Sophia Ladraa *INSERM U1163, Laboratoire de physiopathologie et de traitement des troubles hématologiques, Institut Imagine, Université Paris Cité, Hôpital Universitaire Necker - Enfants Malades, Paris, France.
Zakia BelaidINSERM U1163, Laboratoire de physiopathologie et de traitement des troubles hématologiques, Institut Imagine, Université Paris Cité, Hôpital Universitaire Necker - Enfants Malades, Paris, France.
Isabelle PloINSERM, U1287, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France.ORCID 0000-0002-5915-6910
Sébastien LetardCRCM [Signaling, Hematopoiesis and Mechanism of Oncogenesis, Equipe Labellisée Ligue Contre le Cancer], INSERM U1068 CNRS Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France.ORCID 0000-0002-6508-7376
Erinn SoucieCRCM [Signaling, Hematopoiesis and Mechanism of Oncogenesis, Equipe Labellisée Ligue Contre le Cancer], INSERM U1068 CNRS Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France.
Irena DraskovicInstitut Curie, CNRS UMR 3244, Sorbonne University, PSL Research University, Sorbonne, France.
Nicolas GoudinStructure Fédérative de Recherche (SFR) Necker, Inserm US24 CNRS UAR 3633, Necker Bioimage Analysis Platform, Faculté de Médecine, Paris, France.
Marie BouilliéINSERM U1163, Laboratoire de physiopathologie et de traitement des troubles hématologiques, Institut Imagine, Université Paris Cité, Hôpital Universitaire Necker - Enfants Malades, Paris, France.
Yves LepelletierINSERM U1163, Laboratoire de physiopathologie et de traitement des troubles hématologiques, Institut Imagine, Université Paris Cité, Hôpital Universitaire Necker - Enfants Malades, Paris, France.
Julien RossignolCentre de Référence des Mastocytoses CEREMAST, Hôpital Universitaire Necker - Enfants Malades; Faculté de Médecine de Paris, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Laura PolivkaCentre de Référence des Mastocytoses CEREMAST, Hôpital Universitaire Necker - Enfants Malades; Faculté de Médecine de Paris, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Laurent FrenzelINSERM U1163, Laboratoire de physiopathologie et de traitement des troubles hématologiques, Institut Imagine, Université Paris Cité, Hôpital Universitaire Necker - Enfants Malades, Paris, France.
Olivier LortholaryCentre de Référence des Mastocytoses CEREMAST, Hôpital Universitaire Necker - Enfants Malades; Faculté de Médecine de Paris, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Sylvie FraitagCentre de Référence des Mastocytoses CEREMAST, Hôpital Universitaire Necker - Enfants Malades; Faculté de Médecine de Paris, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Christine BodemerCentre de Référence des Mastocytoses CEREMAST, Hôpital Universitaire Necker - Enfants Malades; Faculté de Médecine de Paris, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Patrick RevyLaboratory of Genome Dynamics in Human Diseases, Equipe Labellisée Ligue contre le Cancer "LIGUE 2023", INSERM UMR 1163, Imagine Institute, Paris, France.
Michel ArockCEREMAST, Hematology Laboratory, Pitié-Salpêtrière Hospital, Paris Sorbonne University, Paris, France.
Thierry-Jo MolinaINSERM U1163, Laboratoire de physiopathologie et de traitement des troubles hématologiques, Institut Imagine, Université Paris Cité, Hôpital Universitaire Necker - Enfants Malades, Paris, France.ORCID 0000-0002-3929-9754
Arturo Londono-VallejoInstitut Curie, CNRS UMR 3244, Sorbonne University, PSL Research University, Sorbonne, France.
Patrice DubreuilCentre de Référence des Mastocytoses CEREMAST, Hôpital Universitaire Necker - Enfants Malades; Faculté de Médecine de Paris, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.ORCID 0000-0003-1155-1150
Leila Maouche-ChretienINSERM U1163, Laboratoire de physiopathologie et de traitement des troubles hématologiques, Institut Imagine, Université Paris Cité, Hôpital Universitaire Necker - Enfants Malades, Paris, France. leila.maouche@inserm.fr.
Olivier HermineINSERM U1163, Laboratoire de physiopathologie et de traitement des troubles hématologiques, Institut Imagine, Université Paris Cité, Hôpital Universitaire Necker - Enfants Malades, Paris, France. ohermine@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mastocytosis, a clonal disorder characterized by the accumulation of mast cells in various tissues, affects both adults and children. Adults frequently exhibit KIT activating mutations, usually in the phospho-transferase domain (PTD KIT mutations). Our previous findings revealed that children also harbor oncogenic KIT activating mutations, but more commonly within the extra-cellular domain (non-PTD KIT mutations). While the disease persists chronically in adults, it often regresses spontaneously in children through an unknown mechanism. Here, we report that tumor senescence in childhood mastocytosis may be triggered by significantly shortened telomeres in mast cells harboring non-PTD KIT mutations compared to those with PTD KIT mutations. In vitro models further demonstrated a senescent phenotype associated with shorter telomeres for the non-PTD KIT mutant compared to the PTD KIT mutant. Mechanistically, we found that telomere shortening in mast cells from children with non-PTD KIT mutations is linked with increased p38 MAP-kinase activation, resulting in lower TRF2 occupancy on telomeres. Thus, non-PTD KIT mutations trigger distinct signaling pathways leading to telomere shortening and cellular senescence, providing mechanistic insights into the differing outcomes between childhood- and adult-onset mastocytosis.

Indexed as

MastocytosisMutationProto-Oncogene Proteins c-kitTelomereTelomeric Repeat Binding Protein 2AdolescentAdultCellular SenescenceChildChild, PreschoolFemaleHumansMaleMast CellsTelomere ShorteningKIT protein, humanProto-Oncogene Proteins c-kitTelomeric Repeat Binding Protein 2TERF2 protein, human

Identifiers

PMID41193460
PMCPMC12589641

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.